Lazard Asset Management
TNGX icon

Lazard Asset Management’s Tango Therapeutics TNGX Stock Holding History

Lazard Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,087
Closed -$54K – 2538
2024
Q3 		$54K Buy
7,087
+6,989
+7,132% +$66.7K ﹤0.01% 1907
2024
Q2 		$0 Sell
98
-2,251
-96% -$17.4K ﹤0.01% 2428
2024
Q1 		$18K Sell
2,349
-1,307
-36% -$14K ﹤0.01% 1850
2023
Q4 		$35K Buy
3,656
+144
+4% +$1.25K ﹤0.01% 1988
2023
Q3 		$38K Buy
3,512
+171
+5% +$1.04K ﹤0.01% 1929
2023
Q2 		$10K Buy
3,341
+97
+3% +$349 ﹤0.01% 2184
2023
Q1 		$12K Buy
3,244
+676
+26% +$3.92K ﹤0.01% 2116
2022
Q4 		$18K Buy
+2,568
New +$18.1K ﹤0.01% 2145

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lazard Asset Management's TNGX Position: Q4 2024 in Review

Lazard Asset Management sold out of Tango Therapeutics (TNGX) in Q4 2024, closing a stake of 7,087 shares — an estimated $54K sold.

Lazard Asset Management first reported a position in TNGX in Q4 2022 and held it in 8 quarters. The position peaked at $54K in Q3 2024. 137 funds tracked by Wall St. Rank hold TNGX as of Q4 2024.

  • Lazard Asset Management reported no remaining Tango Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 7,087 Tango Therapeutics shares in Q4 2024, an estimated $54K.
  • Lazard Asset Management first reported a position in Tango Therapeutics in Q4 2022 and held it in 8 quarters.
  • Lazard Asset Management's Tango Therapeutics position peaked at $54K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.